U.S. patent application number 12/617536 was filed with the patent office on 2010-05-20 for process for making (r)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4-iodophenylamino)-8-met- hylpyrido[2,3-d]pyrimidine-4,7(3h,8h)-dione and intermediates thereof.
This patent application is currently assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED. Invention is credited to Todd Miller, David Paul Provencal, Jonathon S. Salsbury, Yuxin Zhao.
Application Number | 20100125138 12/617536 |
Document ID | / |
Family ID | 41479363 |
Filed Date | 2010-05-20 |
United States Patent
Application |
20100125138 |
Kind Code |
A1 |
Provencal; David Paul ; et
al. |
May 20, 2010 |
PROCESS FOR MAKING
(R)-3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLOURO-4-IODOPHENYLAMINO)-8-MET-
HYLPYRIDO[2,3-d]PYRIMIDINE-4,7(3H,8H)-DIONE AND INTERMEDIATES
THEREOF
Abstract
The present invention relates generally to processes of making
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, intermediates thereof,
and a process for making a particular polymorph of
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione.
Inventors: |
Provencal; David Paul; (San
Diego, CA) ; Miller; Todd; (San Marcos, CA) ;
Zhao; Yuxin; (San Diego, CA) ; Salsbury; Jonathon
S.; (Madison, WI) |
Correspondence
Address: |
TAKEDA SAN DIEGO, INC.
10410 SCIENCE CENTER DRIVE
SAN DIEGO
CA
92121
US
|
Assignee: |
TAKEDA PHARMACEUTICAL COMPANY
LIMITED
Osaka
JP
|
Family ID: |
41479363 |
Appl. No.: |
12/617536 |
Filed: |
November 12, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61115646 |
Nov 18, 2008 |
|
|
|
Current U.S.
Class: |
544/279 ;
546/288; 560/169 |
Current CPC
Class: |
A61P 9/10 20180101; A61P
27/02 20180101; A61P 17/04 20180101; A61P 17/06 20180101; A61P
13/12 20180101; A61P 29/00 20180101; A61P 31/04 20180101; A61P
19/02 20180101; A61P 35/00 20180101; A61P 25/00 20180101; C07D
213/82 20130101; A61P 1/04 20180101; C07D 471/04 20130101; A61P
1/18 20180101; A61P 13/08 20180101; A61P 11/06 20180101; A61P 37/08
20180101; C07C 255/23 20130101; A61P 17/00 20180101; A61P 3/10
20180101; C07D 213/85 20130101; A61P 11/00 20180101 |
Class at
Publication: |
544/279 ;
546/288; 560/169 |
International
Class: |
C07D 471/04 20060101
C07D471/04; C07D 213/84 20060101 C07D213/84; C07C 229/00 20060101
C07C229/00 |
Claims
1. A process for making
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H, 8H)-dione, comprising the step
of reacting a compound of the formula ##STR00014## wherein G.sup.1
is halogen and R.sup.3 and R.sup.4 are independently selected from
the group consisting of hydrogen and suitable hydroxyl protecting
groups with 2-fluoro-4-iodoaniline to give a compound of the
formula ##STR00015## wherein R.sup.3 and R.sup.4 are as defined
above and optional deprotection and optional resolution.
2. A process for making
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, comprising the step of
reacting a compound of the formula ##STR00016## wherein G.sup.1 is
halogen and R.sup.3 and R.sup.4 are independently selected from the
group consisting of suitable hydroxyl protecting groups with
2-fluoro-4-iodoaniline to give a compound of the formula
##STR00017## wherein R.sup.3 and R.sup.4 are the selected hydroxyl
protecting groups and deprotection and optional resolution.
3. A process according to claim 1 wherein G.sub.1 is chloro,
R.sub.3 and R.sub.4 taken together are acetonide, and the
stereochemistry of the starting material and product is the
(R)-configuration.
4. A compound of the formula ##STR00018## wherein R.sup.1 is a
suitable carboxy protecting group.
5. The compound of claim 3 wherein R.sub.1 is methyl.
6. The compound
4,4-dicyano-1-fluoro-3-hydroxy-N-methylbut-3-enamide.
7. A compound of the formula ##STR00019## wherein Q.sup.1 is
selected from the group consisting of amino, hydroxyl, and
halogen.
8. The compound of claim 6 wherein Q.sup.1 is hydroxyl.
9. The compound of claim 6 wherein Q.sup.1 is chloro.
10. A compound the of formula ##STR00020## wherein G.sup.1 is
halogen.
11. A compound of the formula ##STR00021## wherein G.sup.1 is
halogen.
12. A compound of formula ##STR00022## wherein G.sup.1 is
halogen.
13. The compound of claim 11 wherein G.sub.1 is chloro.
14. A compound of the formula ##STR00023## wherein G.sup.1 is
halogen and R.sup.3 and R.sup.4 are independently selected from the
group consisting of hydrogen and suitable hydroxy protecting
groups.
15. A compound of the formula ##STR00024## wherein G.sup.1 is
halogen and R.sup.3 and R.sup.4 are independently selected from the
group consisting of suitable hydroxy protecting groups.
16. The compound of claim 14 wherein the stereochemistry is the
(R)-configuration.
17. The compound of any one of claims 13, 14, and 15 wherein
G.sup.1 is chloro.
18. The compound of claim 15 wherein G.sup.1 is chloro and R.sub.3
and R.sub.4 taken together are acetonide.
19. A process for making Form A polymorph of
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, comprising:
crystallizing
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione in a solvent at a
temperature of about greater than or equal to 40.degree. C.
Description
RELATED APPLICATION
[0001] This application may claim the benefit of U.S. Provisional
Application No. 61/115,646, filed Nov. 18, 2008, which is
incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates generally to chemical
synthesis and preparation of a certain polymorphic form.
BACKGROUND OF THE INVENTION
[0003] The present invention relates to an inhibitor of MEK and/or
ERK activity useful for the treatment a variety of cancerous and
non-cancerous disorders, including brain, lung, squamous cell,
bladder, gastric, pancreatic, breast, head, neck, renal, kidney,
ovarian, prostate, colorectal, colon, epidermoid, esophageal,
testicular, gynecological or thyroid cancer; restenosis; benign
prostatic hypertrophy (BPH)); pancreatitis; kidney disease; pain;
vasculogenesis or angiogenesis (e.g., tumor angiogenesis); acute
and chronic inflammatory disease such as rheumatoid arthritis,
atherosclerosis, inflammatory bowel disease; skin diseases such as
psoriasis, eczema, and scleroderma; diabetes; diabetic retinopathy;
retinopathy of prematurity; age-related macular degeneration;
asthma; neutrophil chemotaxis; septic shock; multiple sclerosis;
chronic obstructive pulmonary disease; and others. Specifically the
present invention relates to
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, see PCT Publication
No. WO2008/079814 published Jul. 3, 2008.
SUMMARY OF THE INVENTION
[0004] The present invention provides a novel process for making
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, characterized by and
comprising the steps of reacting a compound of the formula
##STR00001##
wherein G.sup.1 is halogen and R.sup.3 and R.sup.4 are
independently selected from the group consisting of hydrogen and
suitable hydroxyl protecting groups with 2-fluoro-4-iodoaniline to
give a compound of the formula
##STR00002##
wherein R.sup.3 and R.sup.4 are as defined above and optional
deprotection and optional resolution.
[0005] The present invention also provides intermediates below: a
compound of the formula (a)
##STR00003##
wherein R.sup.1 is a suitable carboxy protecting group;
4,4-dicyano-1-fluoro-3-hydroxy-N-methylbut-3-enamide; a compound of
the formula (b)
##STR00004##
wherein Q.sup.1 is selected from the group consisting of amino,
hydroxyl and halogen; a compound the of formula (c)
##STR00005##
wherein G.sup.1 is halogen; a compound of the formula (d)
##STR00006##
wherein G.sup.1 is halogen; a compound of formula (e)
##STR00007##
wherein G.sup.1 is halogen; and a compound of the formula (f)
##STR00008##
[0006] wherein G.sup.1 is halogen and R.sup.3 and R.sup.4 are
independently selected from the group consisting of hydrogen and
suitable hydroxy protecting groups. The present invention also
provides a process for making Form A polymorph of
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, comprising
crystallizing
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione from a solvent at a
temperature of about greater than about 40.degree. C.
DETAILED DESCRIPTION OF THE INVENTION
[0007] The term "suitable carboxy protecting groups" refers groups
commonly employed to protect the carboxy hydrogen during certain
synthetic steps but can be later removed as desired. The selection
and use of suitable carboxy protecting groups is well known and
appreciated in the art. Examples of suitable carboxy protecting
groups include C.sub.1-6 alkyl, such as methyl, and t-butyl;
C.sub.3-8 cycloalkyl; C.sub.1-20 substituted alkyl carboxy
protecting groups; silyl containing carboxy protecting groups; and
the like.
[0008] The term "C.sub.1-6 alkyl" refers to a saturated, straight
or branched chain having one to six carbon atoms.
[0009] The term "C.sub.3-8 cycloalkyl" refers to a saturated,
optionally branched ring having three to eight carbon atoms.
Examples include cyclopentyl and cyclohexyl.
[0010] The term "C.sub.1-20 substituted alkyl carboxy protecting
groups" refers to a C.sub.1-6 alkyl, most typically methyl and
ethyl, having a various substituents used in carboxy protecting
groups. Examples of C.sub.1-20 substituted alkyl carboxy protecting
groups include methoxymethyl, methylthiomethyl, benzyloxymethyl,
2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethoxy,
2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl,
tetrahydrofuranyl, 2,2,2-chloroethyl, 2-haloethyl,
2-methylthioethyl, picolyl, allyl, and the like. Also included are
optionally substituted benzyl, such as benzyl, p-methyoxybenzyl,
3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-bromobenzyl,
p-chlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, and the like.
[0011] The term "silyl containing carboxy protecting groups,
include trimethylsilyl, triethylsilyl, triisopropylsilyl,
dimethylisopropylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl,
t-butyldiphenylsilyl, and the like.
[0012] The term "halo" or "halogen" refers to fluoro, chloro,
bromo, and iodo.
[0013] The term "suitable hydroxy protecting groups" refers to
groups commonly employed to protect the hydroxyl hydrogen during
certain synthetic steps but can be later removed as desired. The
selection and use of suitable hydroxy protecting groups is well
known and appreciated in the art. Examples of suitable hydroxy
protecting groups include C.sub.1-6 alkyl, such as methyl, and
t-butyl; C.sub.1-20 substituted alkyl hydroxyl protecting groups;
silyl containing hydroxyl protecting groups; 1,2-diol protecting
groups; and the like.
[0014] The term "C.sub.1-20 substituted alkyl hydroxyl protecting
groups" refers to a C.sub.1-6 alkyl, typically methyl and ethyl,
having a various substituents used in hydroxy protecting groups.
Examples of C.sub.1-20 substituted alkyl hydroxy protecting groups
include methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl, and
2,2,2-trichloroethoxymethoxy, 2-(trimethylsilyl)ethoxymethyl,
tetrahydropyranyl, 1-methoxycyclohexyl, tetrahydrofuranyl,
1,4-dioxan-2-yl, 2-ethoxyethyl, 2,2,2-chloroethoxyethyl; picolyl;
allyl; trityl, and the like. Also included are optionally
substituted benzyl, such as including benzyl, p-methyoxybenzyl,
3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-bromobenzyl,
p-chlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, and the like.
[0015] The term "silyl containing hydroxyl protecting groups"
includes those silyl groups used as hydroxyl protecting groups,
such as trimethylsilyl, triethylsilyl, triisopropylsilyl,
dimethylisopropylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl,
t-butyldiphenylsilyl, tribenzylsilyl, triphenylsilyl,
diphenylmethylsilyl, t-butylmethyoxyphenylsilyl, and the like.
[0016] The term "1,2-diol protecting groups" refers to hydroxyl
protecting groups used to protect 1,2-diols with a shared group and
include C.sub.1-14 acetals and ketals, such as methylene,
ethylidene, 1-t-butylethylidene, acetonide, cyclohexylidene,
benzylidine, p-methoxybenzylidene, methoxymethylene, and the like;
and silyl 1,2-diol protecting groups such as di-t-butylsilylene,
1,3-(1,1,3,3-tetraisopropyl)disiloxanylidine, and the like.
[0017] The term "suitable leaving group" refers to group with the
meaning conventionally associated with it in synthetic organic
chemistry, that is, a group capable of being displaced under
alkylating conditions, for example chloro, bromo, iodo, sulfonyloxy
groups, such as trifluoromethanesulfonyloxy, mesyloxy,
benzenesulfonyloxy, tosyloxy, and nosyloxy, and the like.
[0018] The skilled person will appreciate that the compounds of the
present invention may exist as tautomers. The present invention
contemplates all tautomeric forms.
[0019] In another embodiment the invention provides a process for
making
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, characterized by and
comprising the steps of reacting a compound of the formula
##STR00009##
wherein G.sup.1 is halogen and R.sup.3 and R.sup.4 are
independently selected from the group consisting of suitable
hydroxyl protecting groups with 2-fluoro-4-iodoaniline to give a
compound of the formula
##STR00010##
wherein R.sup.3 and R.sup.4 are independently selected form the
group consisting of suitable hydroxyl protecting groups and
deprotection and optional resolution.
[0020] In another embodiment the invention provides compounds of
formula (f)
##STR00011##
wherein G.sup.1 is halogen and R.sup.3 and R.sup.4 are
independently selected from the group consisting of suitable
hydroxy protecting groups.
[0021] General synthetic procedures are set forth in Scheme A. All
substituents, unless otherwise indicated, are as previously
defined. The products in Scheme A can be recovered by conventional
methods including extraction, evaporation, precipitation,
chromatography, crystallization, trituration, and the like.
##STR00012##
[0022] Scheme A, step 1 depicts the reaction of a compound of
formula (1) with malononitrile to give a compound of formula (2). A
compound of formula (1) is one wherein R.sup.1 is a suitable
carboxy protecting group and R.sup.2 is a group which along with
the oxygen to which it is attached is capable of being displaced,
such as methoxy. For example, the reaction is carried out in a
suitable solvent, such as tetrahydrofuran (THF), dioxane,
dimethylsulfoxide (DMSO), dimethylformamide, dimethylacetamide,
methanol, ethanol, isopropanol, acetonitile, and the like. The
reaction is carried out with the use of a suitable base, such as
1,8-diazabicyclo[5.4.0]undecane (DBU),
1,5-diazabicyclo[3.4.0]non-5-ene (DBN), diisopropylethylamine,
triethyl amine, 1,4-diazabicyclo[2.2.2]octane (DABCO), metal
alkoxides such as sodium methoxide and sodium ethoxide, sodium
hydride, potassium t-butoxide, and the like. A molar excess of a
suitable base can be used. Such reactions generally are carried out
at temperature of from about -20.degree. C. to 10.degree. C. and
typically require 1 to 72 hours.
[0023] Scheme A, step 2, depicts the reaction of a compound of
formula (2) with N-methylamine to give the compound of formula (3).
For example, the reaction is carried out in a solvent, such THF,
dioxane, DMSO, dimethylformamide, dimethylacetamide, methanol,
ethanol, isopropanol, water, and the like. An aqueous solution of
N-methylamine can be used and the reagent is generally used in
excess. The reaction is typically carried out at temperatures of
from -20.degree. C. to 50.degree. C. and typically requires 1 to 16
hours.
[0024] Scheme A, step 3, depicts the cyclization of the compound of
formula (3) to give the compound of formula (4). It is understood
the compound of formula (3) first forms the compound
2,4-diamino-5-fluoro-1-methyl-6-oxo-1,6-dihydropyrimidine-carbonitrile,
which is hydrolyzed to give a compound of formula (4). For example,
the reaction is carried out in the presence of a base, such as
sodium hydroxide, metal alkoxides, DBU, DABCO, and the like; in
water, methanol, ethanol, isopropanol; at temperatures of from
10.degree. C. to 50.degree. C.; and typically require 2 to 12
hours.
[0025] Scheme A, step 4, depicts the reaction of a compound of
formula (4) with a suitable halogen converting reagent to give a
compound of formula (5) wherein G.sup.1 is halogen. Suitable
halogen converting reagent refers to a reagent capable of
converting a hydroxyl to halogen, such as, phosphorous oxychloride,
phosphorous pentachloride, phosphorous pentabromide, phosphorous
oxybromide, thionyl chloride, thionyl bromide,
bromine/triphenylphosphine, and the like.
[0026] For example, the reaction typically uses an excess of the
selected suitable halogen converting agent is carried out in a
solvent, such as THF, acetonitrile, and the like. In some cases the
halogen converting reagent can be used as a solvent. The reaction
is typically carried out at temperatures of from 0.degree. C. to
reflux temperature of the selected solvent and typically require 1
to 15 hours. The skilled person will recognize that adducts of
certain halogen converting reagents may be formed and that such
adducts are preferably hydrolyzed to optimize yields.
[0027] Scheme A, step 5, depicts the hydrolysis of a compound of
formula (5) to give a compound of formula (6). For example, the
reaction is carried out in water or dimethylformamide,
dimethylacetamide, toluene, and the like containing water and in
the presence of a suitable acid. The reaction is generally carried
out at temperatures of from 50.degree. C. to 100.degree. C. and
typically require 4 to 10 hours.
[0028] Scheme A, step 6, depicts the reaction of a compound of
formula (6) with a formyl forming reagent and cyclization to give a
compound of formula (7) wherein G.sup.1 is as defined above. It is
understood that the cyclization in step 6 involves a formyl
intermediate and that the cyclization is carried out without
isolation of the product from the formyl formation. For example,
the formyl forming reaction is carried out in a solvent. The
solvent selected will depend on the formyl forming reagent used,
where that reagent is formic acid the solvent is usually water or
the reaction is carried out in formic acid without water being
added. The cyclization is carried out in a solvent such as water
and is generally carried out in the presence of an acid, such as
hydrochloric acid, sulfuric acid, phosphoric acid, and the like.
The reactions are carried out at temperatures of from 50.degree. C.
to 100.degree. C. and typically require 4 to 15 hours.
[0029] Scheme A, step 7, depicts the reaction of a compound of
formula (7) with a 2,3-dihydroxypropyl transfer reagent to give a
compound of formula (8). Step 7 can be carried out using a racemic
or an enantiomerically pure 2,3-dihydroxypropyl transfer reagent.
It is understood that the use of an enantiomerically pure
2,3-dihydroxypropyl transfer reagent generally provides an
enantiomerically pure compound of formula (8). The use of an
enantiomerically pure 2,3-dihydroxypropyl transfer reagent is
preferred. 2,3-Dihydroxypropyl transfer reagents include compounds
of the formulas (10) and (11) below:
##STR00013##
wherein G.sup.2 is a suitable leaving group and R.sup.3 and R.sup.4
are hydrogen or suitable hydroxyl protecting groups and the
stereochemistry is either racemic or enantiomerically pure. Most
conveniently, in compound (10) R.sup.3 and R.sup.4 are taken
together to form a 1,2-diol protecting group. It is to be
understood that step 7 may additionally include one or more
deprotection and/or protection steps. For example, a compound of
formula (10) may give rise to compound of formula (8) in which
R.sup.3 and R.sup.4 are protecting groups, which may be
deprotected, either partially or fully before step 8 to give either
a compound of formula (9) in which R.sup.3 or R.sup.4 is hydrogen
or to directly give a
3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylp-
yrido[2,3-d]pyrimidine-4,7(3H,8H)-dione. Likewise, for example, a
compound of formula (11) will give rise to compound of formula (8)
in which R.sup.3 is hydrogen and R.sup.4 is hydrogen or a
protecting group, which may be used in step 8 to give a compound of
formula (9) in which R.sup.3 is hydrogen and R.sup.4 is a
protecting group or deprotected before use to directly give a
3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylp-
yrido[2,3-d]pyrimidine-4,7(3H,8H)-dione. In addition, for example,
such a compound of formula (8) in which R.sup.3 is hydrogen and
R.sup.4 is a protecting group may have a protecting group added at
R.sup.3 to give a fully protected compound of formula (8). Of
course, other variations of protections and deprotections are
possible and available to the skilled person, all of which are
contemplated to be within the scope of the present process. As used
herein the term "enantiomerically pure" refers to greater than 90%,
preferably greater than 95%, more preferably greater than 97%, most
preferably greater than 99% of the desired isomer. For example, the
reaction is carried out in a solvent, such as THF,
dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dioxane,
and the like. The reaction is carried out with the use of a
suitable base, such as lithium hexamethyldisilazide, lithium
diisopropylamide, potassium carbonate, cesium carbonate, metal
alkoxides, such as potassium t-butoxide, amines, such as
triethylamine, DBU, DBN, DABCO, and the like. The addition of base
is usually carried out at temperature of from about -20.degree. C.
to 30.degree. C. After addition of the protected
2,3-dihydroxyproply transfer reagent the temperature may be raised
to about 20.degree. C. to 80.degree. C. The reaction typically
requires 1 to 72 hours. Such reactions generally are carried out at
temperature of from about -20.degree. C. to 30.degree. C. and
typically require 1 to 72 hours.
[0030] Scheme A, step 8, depicts the reaction of a compound of
formula (8) with 2-fluoro-4-iodoaniline to give a compound of
formula (9). For example, the reaction is carried out in a solvent,
such as THF, dimethylformamide, dimethylacetamide, and the like.
The reaction is carried out with the use of a suitable base. Bases
such as lithium hexamethyldisilazide, lithium diisopropylamide, and
the like are preferred. The addition of base is typically carried
out at temperature of from about -25.degree. C. to 15.degree. C.
After the base is added the temperature may be raised to about
20.degree. C. to 90.degree. C. The reaction typically requires 1 to
72 hours.
[0031] Alternately, for example, the reaction can be carried out in
the presence of catalyst, such as a palladium [0] or [II] catalyst.
The palladium catalyst can be prepared with a phosphine ligand,
such as PPh.sub.3, P(t-Bu).sub.3, dppf, tricyclohexylphosphine,
Xantphos, Dave's phos, bis(di-t-Butylphosphino)ferrocene, DEPphos,
X-phos. The reaction is carried out in a solvent, such as THF and
dioxane. The reaction is carried out with the use of a suitable
base, such as sodium t-butoxide, potassium t-butoxide, potassium
hydroxide, and sodium hydroxide. The reaction is typically carried
out at temperature of from about 25.degree. C. to 100.degree. C.
The reaction typically requires 16 to 72 hours.
[0032] Scheme A, step 9, depicts the deprotection of a compound of
formula (9) to give
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione. The term
"deprotection" refers to the procedure by which a protecting group
is removed. Such deprotections of are well known an appreciated in
the art. The use and removal of protecting groups is well known in
the art. See for example, Protecting Groups in Organic Synthesis,
Theodora Greene (Wiley-Interscience)).
[0033] In an additional, optional step, not shown, a racemic
mixture is resolved to give enantiomerically pure product. It is
also understood that the product of the present process may be used
as a pharmaceutically acceptable salt which would be formed in an
optional step, not shown, if desired.
[0034] It is understood that the order of certain steps is not
critical in the process of the present invention. For example,
while the introduction of G.sup.1 is depicted in step 4, this group
can be introduced at any point before the reaction with
2-fluoro-4-iodoaniline depicted in step 8. Additionally it is
understood that an optional resolution, if necessary, can be
carried out before or after step 9.
[0035] The synthetic process of the present invention allows for
the preparation of
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione while avoiding the use
of a fluorinating reagent in the last step. That is, the present
invention provides a valuable process for making
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione characterized by the
reaction of a compound of formula (8) with 2-fluoro-4-iodoaniline
to give a compound of formula (9). Such a process avoids the use of
costly and possible hazardous fluorinating regents in later steps
which has significant advantages in large-scale manufacture.
[0036] The present invention also provides a process for making
Form A polymorph of
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione by crystallizing
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione at a temperature of
about 40.degree. C. or more. The formation of Form A is generally
carried out in a solvent. In practice suitable solvents C.sub.1-3
carboxylic acid, C.sub.3-7 alkylacetate, C.sub.1-6 alcohol,
C.sub.2-8 ether, and C.sub.3-7 alkanone. Anti-solvents, that is, a
solvent or solvents in which the compound is less soluble than in
the selected solvent can also be used. As used herein the term
"C.sub.1-3 carboxylic acid" refers to alkanoic acid having from one
to three carbon atoms, for example, formic, acetic, and propionic
acid; "C.sub.3-7 alkylacetate" refers to straight or branched alkyl
esters of acetic acid having a total of three to seven carbons; the
term "C.sub.1-6 alcohol" a straight or branched alkanols having
from one to six carbon atoms, for example methanol, ethanol,
n-propanol, iso-propanol, 1,3-propanediol, and the like; the term
"C.sub.2-8 ether" refers to a straight, branched, or cyclic alkyl
ethers having a total of from two to eight carbon atoms, for
example diethyl ether, methyl-t-butyl ether, THF, dioxane, and the
like; and the term "C.sub.3-7 alkanones" refers to a straight or
branched alkyl chain having an oxo group and having a total of from
three to seven carbon atoms, for example acetone and methyl ethyl
ketone.
[0037] It is understood that the terms "crystallize,"
"crystallizing,` and "crystallization" to complete dissolution
followed by precipitation and slurry processes that do not involve
complete dissolution. Slurry processes include those that encompass
continuation of stirring following precipitation.
[0038] For example, non-Form A
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione is crystallized from a
solvent at temperature of about 40.degree. C. or higher. The
temperature can range up to the reflux temperature of the selected
solvent and is usually less than 115.degree. C. Where the
crystallization involves complete dissolution, a slow cooling is
preferred. Crystallization to give Form A does not require complete
dissolution. Slurry processes can be used. A slurry can be formed
by processing without complete dissolution or by complete
dissolution followed by processing after initial precipitation. In
a slurry process the volume should be sufficient to provide
free-flowing slurry.
[0039] In one embodiment non-Form A
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione is crystallized from a
solvent at temperature of about 50.degree. C. or higher. In another
embodiment non-Form A
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione is crystallized from a
solvent at temperature of about 60.degree. C. or higher.
[0040] The solvent should be one in which
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione is somewhat soluble.
The volume of solvent is not critical but should be kept to a
minimal amount as a matter of convenience. Optionally, the
crystallization may be seeded with Form A. Such processes generally
require 2 hours to seven days. According to the present process
Form A
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione may be prepared in
substantially pure. The term "substantially pure" refers to greater
than 90%, preferably greater than 97%, more preferably greater than
99%, and even more preferably greater than 99.8% polymorphic
purity.
[0041] The starting material for the present crystallization
process can be any form of
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, including Form A, a
non-Form A polymorph in admixture with Form A, or a non-Form A
polymorph.
[0042] Form A can be characterized by X-ray diffraction. The peaks
were measured using a powder diffractometer equipped with a copper
source, primary beam monochromator, and position sensitive
detector. The incident beam was collimated using a 1.degree.
divergence slit. The source was operated at 40 kV and 30 mA. X-ray
powder diffraction data were collected from 3 degrees to 45 degrees
using a step width of 0.04 degree. The diffractometer was well
calibrated with a silicon standard. Form A was found to have the
following peaks in degrees 2-theta, rounded to 2 significant
figures (relative intensity): 11.03 (34%), 15.88 (15%), 16.26
(100%), 19.32 (90%), 20.11 (15%), 22.16 (23%), 26.66 (17%), 27.84
(33%), and 30.18 (17%).
[0043] Form A
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione is characterized by
peaks at 11.03, 16.26, 19.32, 20.11, 22.16, or 27.84 2-theta, Form
A
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione is also characterized
by peaks at 16.26 and 19.32 2-theta; 16.26 and 27.84 2-theta; 19.32
and 27.84 2-theta; 11.03 and 16.26 2-theta; 11.03 and 19.32
2-theta; 11.03, 16.26 and 19.32 2-theta; 16.26, 19.32, and 27.84
2-theta; 19.32, 22.16, and 27.84 2-theta; 11.03, 16.26, 19.32, and
27.84 2-theta; and 11.03, 16.26, 19.32, 20.11, 22.16, and 27.84
2-theta.
[0044] It is recognized that the relative intensity of X-ray
diffraction peaks can be dependent on preferred orientation and
other factors. Therefore, a sample of Form A may require processing
to mitigate such factors, such as grinding the sample in an agate
mortar and pestle or other measures. It is understood that
differences in relative intensity of the diffraction peaks does not
preclude an acquired pattern from being consistent with Form A.
[0045] Form A can also be characterized by differential scanning
calorimetry. A thermogram of Form A provides a single endothermic
event at 238-240.degree. C. which was consistent with a melt.
[0046] In order that the invention be more fully understood the
foregoing processes are exemplified below. These examples are
understood to be illustrative only and are not intended to limit
the scope of the invention in any way:
Example 1
2-Amino-5-fluoro-4-hydroxy-1-methyl-6-oxo-1,6-dihydropyridine-carbonitrile
[0047] Combine dimethylfluoromalonate (10 g, 0.066 mol) and
malononitrile (4.4 g, 0.066 mol) in THF (50 mL) and cool to about
-35.degree. C. Add DBU (20 mL, 0.128 mol) over about 20 minutes
while keeping the internal temperature below about -25.degree. C.
When the addition of DBU is complete, slowly warm to ambient
temperature. After 18 hours, slowly add aqueous methylamine (40%,
30 mL, 0.44 mol). After 2 hours, add aqueous sodium hydroxide (10
M, 1 mL). After 3 hours, evaporate in vacuo to obtain a largely
aqueous residue, cool to about 0.degree. C., add concentrated
hydrochloric acid (about 5 mL) to a pH of about 1 to give a solid.
Collect the solid by filtration and rinse with water and ethanol
(10 mL) to give the title compound. .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 11.71 (s, 1H), 7.29 (s, 2H), 3.27 (s, 3H); .sup.13C NMR
(100 MHz, DMSO-d6) .delta. 154.7 (d, J=21.9 Hz), 153.1, 151.4 (d,
J=13.2 Hz), 129.5 (d, J=211 Hz), 115.4 (d, J=3.7 Hz), 63.2 (d,
J=2.9 Hz), 28.7; .sup.19F NMR (376 MHz, DMSO-d6) .delta. -178.9; MS
(M+H)+m/z calcd 184.0, found 184.0.
Example 2
2-Amino-5-fluoro-4-chloro-1-methyl-6-oxo-1,6-dihydropyridine-carbonitrile
[0048] Combine
2-amino-5-fluoro-4-hydroxy-1-methyl-6-oxo-1,6-dihydropyridine-carbonitril-
e (30.0 g, 0.164 mol) and anhydrous acetonitrile (150 mL). Slowly
add phosphorous oxychloride (37 mL). After addition is complete
heat to reflux. After 3 hours, cool to ambient temperature and then
in an ice-bath. Add another portion of acetonitrile (150 mL).
Slowly add to ice-water (300 mL, 10 volumes). Heat to about
50.degree. C. After 5 hours, cool in an ice bath to give a solid,
filter, rinse the solid with water, and dry in vacuo to give the
title compound. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.73 (s,
2H). 3.33 (s, 3H); .sup.13C NMR (100 MHz, DMSO-d6) .delta. 153.3
(d, J=32.9 Hz), 139.2, 136.9, 128.5 (d, J=16.9 Hz), 115.3 (d, J=2.2
Hz), 68.1, 29.7 (d, J=1.4 Hz); .sup.19F NMR (376 MHz, DMSO-d6)
.delta. -152.0; MS (M+H)+m/z calcd 202.0, found 202.0. Combine the
title compound (4.4 g) in 40 mL of dimethylacetamide (40 mL) and
heat to 38.degree. C. Add activated carbon (4.4 g). After 30
minutes filter through Celite.RTM., rinse with dimethylacetamide,
and add water to the filtrate, then cool in an ice bath to give a
solid. Collect the solid by filtration, rinse with water (20 mL),
and dry in vacuo at give the title compound.
Example 3
5-Chloro-6-fluoro-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,
8H)-dione
[0049] Combine
2-amino-5-fluoro-4-chloro-1-methyl-6-oxo-1,6-dihydropyridine-carbonitrile
(33.0 g, 0.164 mol) and 99% formic acid (264 mL, 8 volumes) in a
dried vessel. Heat to 70.degree. C. When a solution is formed, add
concentrated aqueous hydrochloric acid (165 mL, 5 volumes). After
20 hours, add another portion of concentrated aqueous hydrochloric
acid (35 mL) and heated at 70.degree. C. for another 4h. Then cool
the reaction mixture to the ambient temperature and add ice-water
(350 mL, 10 volumes). Cool in an ice bath to give a solid. After 30
minutes, collect the solid by filtration, rinse with water
(2.times.30 mL), and dry in vacuo to give the title compound.
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 12.96 (s, 1H), 8.35 (s, 1H).
3.61 (s, 3H); .sup.13C NMR (100 MHz, DMSO-d6) .delta. 157.7 (d,
J=4.4 Hz), 154.6 (d, J=26.4 Hz), 151.2 (d, J=2.2 Hz), 149.9, 146.4
(d, J=242 Hz), 125.0 (d, J=16.9 Hz), 99.94, 29.8; .sup.19F NMR (376
MHz, DMSO-d6) .delta. -133.8; MS (M+H)+m/z calcd 230.0, found
230.0.
Example 4.1
5-Chloro-6-fluoro-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
[0050] Combine
2-amino-5-fluoro-4-chloro-1-methyl-6-oxo-1,6-dihydropyridine-carbonitrile
(4.97 g, 246 mmol) and 99% formic acid (40 mL, 8 volumes) in a
dried vessel. Heat to 80.degree. C. When a solution is formed add
aqueous 9 N sulfuric acid (25 mL, 5 volumes). After 20 hours, cool
ambient temperature and add ice-water (50 mL, 10 volumes) with
stirring. Cool in an ice bath to give a solid. After 30 minutes,
collect the solid by filtration, rinse with water (2.times.5 mL),
and dry in vacuo to give the title compound.
Example 4.2
5-Chloro-6-fluoro-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
[0051] Combine
2-amino-5-fluoro-4-chloro-1-methyl-6-oxo-1,6-dihydropyridine-carbonitrile
(50.0 g, 0.248 mol) and 88% formic acid (400 mL, 8 volumes) in a
dried vessel. Add concentrated (96%) sulfuric acid (125 mL, 2.5
volumes) slowly added to the mixture at below room temperature to
give a solution. Heat at 70.degree. C. for 24 hours. Cool below the
ambient temperature and slowly add water (625 mL, 12.5 volumes)
while maintaining the temperature below ambient temperature to give
a slurry. After 4 hours, collect the solid by filtration, rinse
with water (2.times.100 mL), and dry in vacuo to give the title
compound.
Example 5.1
(R)-5-Chloro-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-8-methylp-
yrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
[0052] Combine
5-chloro-6-fluoro-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
(20.0 g, 87.1 mmol) and dimethylacetamide (100 mL, 5 volumes) in a
dried vessel. Cool in an ice-bath then add lithium
hexamethyldisilazide (1 M/L in THF, 96.0 mL, 96.0 mmol). After 5
minutes, add (S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl
4-nitrobenzenesulfonate (30.4 g, 95.7 mmol). Slowly heat to
60.degree. C. After 15 hours, cool to ambient temperature and
evaporate the THF in vacuo, cool the remaining mixture in an
ice-bath and then add ice-water (60 mL, 3 volumes) to give a solid.
Collect the solid by filtration, rinse with water, and dry in
vacuo. Combine the solid (24.0 g) in iso-propyl acetate (170 mL,
.about.7 volumes) and heat to reflux. After 3 hours, cool to
ambient temperature to give a solid. Collect the solid by
filtration, rinse with iso-propylacteate/heptane (20 mL, 1:1 by
volume), and dry in vacuo to give the title compound. .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.58 (s, 1H), 4.38 (m, 1H), 4.22 (dd,
1H, J=13.6, 3.6 Hz), 4.07 (dd, 1H, J=8.4, 6.4 Hz), 3.94 (dd, 1H,
J=13.6, 7.6 Hz), 3.76 (dd, 1H, J=8.8, 5.2 Hz), 3.61 (s, 3H), 1.37
(s, 3H), 1.24 (s, 3H); .sup.13C NMR (100 MHz, DMSO-d6) .delta.
157.0 (d, J=3.6 Hz), 154.5 (d, J=25.6 Hz), 152.4, 150.5 (d, J=2.2
Hz), 146.8 (d, J=243 Hz), 124.9 (d, J=17.6 Hz), 109.1, 99.1, 72.3,
66.1, 48.8, 29.7, 26.5, 25.0; HRMS (QSTAR) (M+H)+m/z calcd
344.0808, found 344.0799.
Example 5.2
(R)-5-Chloro-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-8-methylp-
yrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
[0053] Combine
5-chloro-6-fluoro-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
(5.00 g, 21.8 mmol),
(S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl-4-nitrobenzenesulfonate
(7.60 g, 24.0 mmol), and N-methylpyrrolidinone (25.0 mL, 259 mmol).
Add 1,8-Diazabicyclo[5.4.0]undec-7-ene (3.58 mL, 24.0 mmol) to the
suspension. Heat to 60.degree. C. and stir overnight. Add isopropyl
acetate (50.0 mL, 427 mmol) followed by water (50.0 mL, 2780 mmol)
while maintaining the temperature above 50.degree. C. Stir at
60.degree. C. for 1 hour, separate the phases and transfer the
aqueous phase to a flask. Add isopropyl acetate (50.0 mL, 427 mmol)
to the flask and stir at 60.degree. C. for 1 hour and then separate
the layers. Combine the organic phases and concentrate under vacuum
to about 25 mL to give a solid. Cool to ambient temperature and
stir for no longer than 2 hours, collect the solid by filtration,
dry under vacuum overnight to give the title compound.
Example 6.1
(R)-3-((2,2-Dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-(2-fluoro-4-iodo-
phenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
[0054] Combine
(R)-5-chloro-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-8-methyl-
pyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (5.00 g, 14.5 mmol) and
2-fluoro-4-iodoaniline (3.45 g, 14.5 mmol) in THF (25 mL). Cool in
an ice-bath. Add lithium hexamethyldisilazide (1.0 M in THF, 36.4
mL, 36.4 mmol) maintaining the temperature below about 10.degree.
C. After 10 minutes, warm to ambient temperature. After 30 minutes,
heat to 55.degree. C. After 20 hour, cool to ambient temperature,
add dimethylacteamide (35 mL) and evaporate in vacuo to remove most
of the THF. Cool the remaining mixture in an ice-bath then add
water (17.5 mL) to form a solid. Add water (20 mL), then collect
the solid by filtration, rinse with water (3.times.15 mL), heptane
(15 mL), and dry in vacuo to give the title compound. .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 10.14 (s, 1H), 8.60 (s, 1H), 7.68 (d,
1H, J=10.4, 2.0 Hz), 7.52 (d, 1H, J=8.8 Hz), 6.96 (td, 1H, J=8.8,
6.0 Hz), 4.41 (m, 1H), 4.25 (dd, 1H, J=13.6, 3.6 Hz), 4.06 (dd, 1H,
J=8.8, 6.4 Hz), 3.98 (dd, 1H, J=13.6, 7.6 Hz), 3.78 (dd, 1H, J=9.2,
5.6 Hz), 3.58 (s, 3H), 1.37 (s, 3H), 1.23 (s, 3H); .sup.13C NMR
(100 MHz, DMSO-d6) .delta. 161.1 (d, J=4.4 Hz), 155.7 (d, J=8.8
Hz), 155.4, 153.3, 151.1 (d, J=109 Hz), 135.6, 133.6 (d, J=7.3 Hz),
133.1 (d, J=3.7 Hz), 127.9 (d, J=13.2 Hz), 125.2 (d, J=6.5 Hz),
123.9 (d, J=21.9 Hz), 109.1, 95.1 (d, J=4.4 Hz), 87.1 (d, J=7.3
Hz), 72.2, 66.1, 48.9, 28.8, 26.6, 25.0; .sup.19F NMR (376 MHz,
DMSO-d6) .delta. -124.5, -149.3; MS (M+H)+m/z calcd 545.0, found
545.0.
Example 6.2
(R)-3-((2,2-Dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-(2-fluoro-4-iodo-
phenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
[0055] Combine
(R)-5-chloro-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-8-methyl-
pyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (4.00 g, 11.6 mmol),
2-fluoro-4-iodoaniline (2.76 g, 11.6 mmol) and tetrahydrofuran
(16.0 mL, 197 mmol). Cool to 0.degree. C. to 5.degree. C. in an ice
bath, add 1.0 M lithium hexamethyldisilazide in tetrahydrofuran
(23.3 mL, 23.3 mmol) while keeping the temperature below 10.degree.
C. Agitate in an ice bath for no less than 30 min and then warm to
ambient temperature and stir overnight. Add water (20.0 mL) and
methylene chloride (40.0 mL) and agitate, then separate the phases.
Combine the organic phase and 40 mL of water, adjust the pH to 7
with 2 N HCl. Separate the organic phase extract with water (20
mL), dry over MgSO.sub.4, concentrate to 20 mL to give a solid. Add
isopropyl acetate (40.0 mL, 342 mmol) to the suspension, stir at
ambient temperature for no less than 2 hours, collect the solid by
filtration, rinse with isopropyl acetate (20 mL), and dry overnight
at 30.degree. C. under vacuum to give the title compound.
Example 7
(R)-3-((2,2-Dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-(2-fluoro-4-iodo-
phenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
[0056] Combine
(R)-5-chloro-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-8-methyl-
pyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (0.050 g, 0.15 mmol) and
2-fluoro-4-iodoaniline (0.052 g, 0.22 mmol) in de-gassed dioxane
(2.0 mL). Add palladium acetate (1.6 mg) and Xantphos (8.5 mg) and
sodium t-butoxide (35 mg). Heat to 85.degree. C. After 2 hours,
dilute with ethyl acetate, wash with aqueous hydrochloric acid and
then brine, dry over sodium sulfate, and concentrate in vacuo to
give a residue. Purify the residue with flash chromatography
eluting with ethyl acetate/hexane to give the title compound.
Example 8.1
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
[0057] Combine
(R)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-(2-fluoro-4-iod-
ophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
(24.75 g, 45.58 mmol) and ethanol (250 mL). Add aqueous 9N sulfuric
acid (50 mL) over 5 minutes. Heat to 75.degree. C. After 2 hour,
cool to ambient temperature and then cool in an ice bath to give a
solid. Collect the solid by filtration, rinse with ethanol
(3.times.30 mL), and dry to give the title compound. .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 10.24 (s, 1H), 8.52 (s, 1H), 7.69 (dd,
1H, J=10.4, 1.8 Hz), 7.52 (d, 1H, J=8.6 Hz), 6.98 (m, 1H), 5.14
(brs, 1H), 4.83 (brs, 1H), 4.32 (dd, 1H, J=12.9, 2.5 Hz), 3.76 (m,
1H), 3.67 (dd, 1H, J=13.1, 12.9 Hz), 3.58 (s, 3H), 3.46 (ddd, 1H,
J=10.9, 5.3, 5.1 Hz), 3.38 (m, 1H); .sup.13C NMR (100 MHz, DMSO-d6)
.delta. 161.3 (d, J=4.0 Hz), 155.6 (d, J=22.8 Hz), 154.6 (d, J=250
Hz), 152.0, 150.6, 134.3 (d, J=231 Hz), 133.8 (d, J=7.1 Hz), 133.1
(d, J=3.0 Hz), 127.8 (d, J=10.3 Hz), 125.3 (d, J=7.0 Hz), 123.9 (d,
J=21.5 Hz), 95.0 (d, J=4.0 Hz), 87.1 (d, J=7.8 Hz), 68.0, 63.8,
50.1, 28.8; .sup.19F NMR (376 MHz, DMSO-d6) .delta. -124.4, -149.8;
MS (M+H)+ m/z calcd 505.0, found 505.0.
Example 8.2
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0058] Combine
(R)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-(2-fluoro-4-iod-
ophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
(0.50 g, 0.919 mmol), methanol (5.0 mL) and 6.00 M hydrochloric
acid (0.50 mL, 3.0 mmol) and heat to 60.degree. C. After 2 hours,
cool to 50.degree. C. and stir for 24 hours, then cool to ambient
temperature, filter to collect the solid, rinse with methanol, and
dry under vacuum at 30.degree. C. to give the title compound.
Example 9
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0059] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (19.89 g) in methanol (300
mL), heat to 60.degree. C., and stir. After 48 hours, cool to
ambient temperature. After 30 minutes, collect the solid by
filtration and dry at 40.degree. C. in vacuo to give the title
compound.
Example 10
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0060] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in ethyl acetate (2.0
mL). Seal, heat to 40.degree. C., and stir. After 24 hours, cool to
ambient temperature. Collect the solid by filtration and dry to
give the title compound.
Example 11
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0061] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in ethanol (2.0 mL).
Seal, heat to 40.degree. C., and stir. After 24 hours, cool to
ambient temperature. Collect the solid by filtration and dry to
give the title compound.
Example 12
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0062] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in methanol (2.0 mL).
Seal, heat to 40.degree. C., and stir. After 24 hours, cool to
ambient temperature. Collect the solid by filtration and dry to
give the title compound.
Example 13
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0063] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in ethyl acetate (2.0
mL). Seal and stir at ambient temperature. After 24 hours, collect
the solid by filtration and dry to give the title compound.
Example 14
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0064] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in ethanol (2.0 mL).
Seal and stir at ambient temperature. After 48 hours, collect the
solid by filtration and dry to give the title compound.
Example 15
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0065] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in methanol (2.0 mL).
Seal and stir at ambient temperature. After 24 hours, collect the
solid by filtration and dry to give the title compound.
Example 16
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0066] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in ethyl acetate (2.0
mL). Seal, heat to 40.degree. C., and stir. After 30 minutes, add 5
mg of Form A. After 24 hours, cool to ambient temperature. Collect
the solid by filtration and dry to give the title compound.
Example 17
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0067] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in ethanol (2.0 mL).
Seal, heat to 40.degree. C., and stir. After 30 minutes, add 5 mg
of Form A. After 24 hours, cool to ambient temperature. Collect the
solid by filtration and dry to give the title compound.
Example 18
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0068] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in methanol (2.0 mL).
Seal, heat to 40.degree. C., and stir. After 30 minutes, add 5 mg
of Form A. After 24 hours, cool to ambient temperature. Collect the
solid by filtration and dry to give the title compound.
Example 19
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0069] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in ethyl acetate (2.0
mL). Seal and stir at ambient temperature. After 30 minutes, add 5
mg of Form A. After 24 hours, collect the solid by filtration and
dry to give the title compound.
Example 20
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0070] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in ethanol (2.0 mL).
Seal and stir at ambient temperature. After 30 minutes, add 5 mg of
Form A. After 24 hours, collect the solid by filtration and dry to
give the title compound.
Example 21
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0071] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.10 g) in methanol (2.0 mL).
Seal and stir at ambient temperature. After 30 minutes, add 5 mg of
Form A. After 24 hours, collect the solid by filtration and dry to
give the title compound.
Example 22
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0072] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (3.0 g) in ethanol (60.0 mL).
Seal, heat to 40.degree. C. and stir. After 24 hours, cool to
ambient temperature. Collect the solid by filtration and dry to
give the title compound.
Example 23
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0073] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione amorphous material
(characterized by X-ray diffraction patterns without discernable
peaks and microscopy analysis under cross-polarized light which
showed little to no birefringence) (30 mg) in tetrahydrofuran (1.0
mL). Seal and stir at ambient temperature. After one week, collect
the solid by filtration and dry to give the title compound.
Example 24
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0074] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione amorphous material
(characterized by X-ray diffraction patterns without discernable
peaks and microscopy analysis under cross-polarized light which
showed little to no birefringence) (20 mg) in acetone (1.0 mL).
Seal and stir at ambient temperature. After six days, collect the
solid by filtration and dry to give the title compound.
Example 25
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0075] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione amorphous material
(characterized by X-ray diffraction patterns without discernable
peaks and microscopy analysis under cross-polarized light which
showed little to no birefringence) (0.3 g) in acetone (15.0 mL).
Seal and stir at ambient temperature. After six days, collect the
solid by filtration and dry to give the title compound.
Example 26
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0076] Suspend
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (characterized by X-ray
diffraction peaks at 22.61 and 18.42 degrees 2-theta and one
endothermic event at 231.degree. C.) (0.50 g) in ethanol (10 mL).
Seal, heat to 50.degree. C., and stir. After 30 minutes, add 25 mg
of Form A. After 24 hours, cool to ambient temperature. Collect the
solid by filtration and dry to give the title compound.
Example 27
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-meth-
ylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione Form A
[0077] Dissolve
(R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-met-
hylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione (19.9 g) in acetic acid
(0.8 mL) at 75.degree. C., filter, and transfer into a preheated
vial. Add toluene (1.5 mL in aliquots) and cool to ambient
temperature at a rate of 20.degree. C./h. After 24 hours, collect
the solid by filtration, and dry in vacuo at ambient temperature to
give the title compound.
* * * * *